Role of synbiotics in polysaccharide assisted colon targeted microspheres of mesalamine for the treatment of ulcerative colitis.

[1]  S. Singh,et al.  Effect of co-administration of probiotics with polysaccharide based colon targeted delivery systems to optimize site specific drug release. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  Wang Hao,et al.  Pectin-chitosan complex: Preparation and application in colon-specific capsule , 2015 .

[3]  S. Singh,et al.  A novel dissolution method for evaluation of polysaccharide based colon specific delivery systems: A suitable alternative to animal sacrifice. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  Ashwin N. Ananthakrishnan,et al.  Epidemiology and risk factors for IBD , 2015, Nature Reviews Gastroenterology &Hepatology.

[5]  E. Clementi,et al.  Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug , 2015, Gastroenterology research and practice.

[6]  A. Lyra,et al.  Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. , 2014, World journal of gastroenterology.

[7]  S. Singh,et al.  Facts, fallacies and future of dissolution testing of polysaccharide based colon-specific drug delivery. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Q. Dang,et al.  Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization , 2014, Pharmaceuticals.

[9]  A. Attama,et al.  Nanovesicular carriers as alternative drug delivery systems: ethosomes in focus , 2014, Expert opinion on drug delivery.

[10]  Gabriel Núñez,et al.  Control of pathogens and pathobionts by the gut microbiota , 2013, Nature Immunology.

[11]  X. Zhou,et al.  The possible effects of mesalazine on the intestinal microbiota , 2012, Alimentary pharmacology & therapeutics.

[12]  D. Raoult,et al.  Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. , 2012, Microbial pathogenesis.

[13]  A. Moss,et al.  Mesalamine in the treatment and maintenance of remission of ulcerative colitis , 2012, Expert review of clinical pharmacology.

[14]  G. Dadlani,et al.  Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report , 2011, Case reports in pediatrics.

[15]  L. Leifeld,et al.  Mesalazine granules are superior to Eudragit‐L‐coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis , 2011, Alimentary pharmacology & therapeutics.

[16]  S. Katsuki,et al.  Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis , 2011, Case Reports in Gastroenterology.

[17]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[18]  Tin Wui Wong,et al.  Pectin Matrix as Oral Drug Delivery Vehicle for Colon Cancer Treatment , 2011, AAPS PharmSciTech.

[19]  G. S. Hassan,et al.  Design, synthesis and anti-ulcerogenic effect of some of furo-salicylic acid derivatives on acetic acid-induced ulcerative colitis. , 2010, European journal of medicinal chemistry.

[20]  D. Mishra,et al.  5-fluorouracil loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro release. , 2009, Yao xue xue bao = Acta pharmaceutica Sinica.

[21]  M. Surette,et al.  Effects of mesalamine (5‐aminosalicylic acid) on bacterial gene expression , 2009, Inflammatory bowel diseases.

[22]  K. Kaulback,et al.  Systematic review: impact of non‐adherence to 5‐aminosalicylic acid products on the frequency and cost of ulcerative colitis flares , 2009, Alimentary pharmacology & therapeutics.

[23]  I. Gorelov,et al.  Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.

[24]  A. Basit,et al.  An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Y. Krishnaiah,et al.  Effect of 5-Fluorouracil Pretreatment on the In Vitro Drug Release from Colon-Targeted Guar Gum Matrix Tablets , 2008 .

[26]  Wei He,et al.  Biphasic drug release: permeability and swelling of pectin/ethylcellulose films, and in vitro and in vivo correlation of film-coated pellets in dogs. , 2008, Chemical & pharmaceutical bulletin.

[27]  M. Kamm,et al.  MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations , 2008, Alimentary pharmacology & therapeutics.

[28]  M. Khan,et al.  Comparative Evaluation of Flow for Pharmaceutical Powders and Granules , 2008, AAPS PharmSciTech.

[29]  He Wei,et al.  Pectin/Ethylcellulose as film coatings for colon-specific drug delivery: preparation and in vitro evaluation using 5-fluorouracil pellets. , 2007, PDA journal of pharmaceutical science and technology.

[30]  H. Hagar,et al.  Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. , 2006, Pharmacological research.

[31]  G. Radford-Smith,et al.  Comparison of the efficacy and safety of Eudragit‐L‐coated mesalazine tablets with ethylcellulose‐coated mesalazine tablets in patients with mild to moderately active ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[32]  S. Kane.  Systematic review: adherence issues in the treatment of ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[33]  J. Bowen,et al.  Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor‐bearing DA rats , 2005, International journal of cancer.

[34]  Y. Krishnaiah,et al.  Development of colon‐targeted albendazole‐β‐cyclodextrin‐complex drug delivery systems , 2005 .

[35]  S. Hanauer,et al.  Update on the etiology, pathogenesis and diagnosis of ulcerative colitis , 2004, Nature Clinical Practice Gastroenterology &Hepatology.

[36]  R Balfour Sartor,et al.  Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. , 2004, Gastroenterology.

[37]  J. Hampe,et al.  Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease , 2004, Gut.

[38]  V. Mai,et al.  Colonic bacterial flora: changing understandings in the molecular age. , 2004, The Journal of nutrition.

[39]  G. Macfarlane,et al.  Intestinal bacteria and ulcerative colitis. , 2003, Current issues in intestinal microbiology.

[40]  V. Sinha,et al.  Binders for colon specific drug delivery: an in vitro evaluation. , 2002, International journal of pharmaceutics.

[41]  M. Langman,et al.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines , 2002, Gut.

[42]  V. Satyanarayana,et al.  In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[43]  M. A. Kamm,et al.  Maintenance of remission in ulcerative colitis , 2002, Alimentary pharmacology & therapeutics.

[44]  V. Satyanarayana,et al.  Guar gum as a carrier for colon specific delivery; influence of metronidazole and tinidazole on in vitro release of albendazole from guar gum matrix tablets. , 2001, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[45]  A. Markham,et al.  Prolonged-Release Mesalazine , 2000, Drugs.

[46]  P. Marcellin,et al.  Mesalazine (5-aminosalicylic acid) induced chronic hepatitis , 1999, Gut.

[47]  S. Satyanarayana,et al.  Studies of guar gum compression-coated 5-aminosalicylic acid tablets for colon-specific drug delivery. , 1999, Drug development and industrial pharmacy.

[48]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.

[49]  L. Vervoort,et al.  In vitro degradation by colonic bacteria of inulinHP incorporated in Eudragit RS films , 1996 .

[50]  B. Korelitz,et al.  Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study. , 1993, Journal of clinical gastroenterology.

[51]  J. Rokem,et al.  In Vitro Evaluation of Calcium Pectinate: A Potential Colon-Specific Drug Delivery Carrier , 1993, Pharmaceutical Research.

[52]  A. Sintov,et al.  Colonic Drug Delivery: Enhanced Release of Indomethacin from Cross-Linked Chondroitin Matrix in Rat Cecal Content , 1992, Pharmaceutical Research.

[53]  S. Krigstin,et al.  Effect of Preparation Parameters on the Formation of Lignin Acetate Microspheres , 2015 .

[54]  D. Raoult,et al.  An evaluation of the effects of Lactobacillus ingluviei on body weight, the intestinal microbiome and metabolism in mice. , 2012, Microbial pathogenesis.

[55]  H. Jain,et al.  Colon-targeted quercetin delivery using natural polymer to enhance its bioavailability , 2011, Pharmacognosy research.

[56]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[57]  J. Newton,et al.  Amylose, the new perspective in oral drug delivery to the human large intestine , 1995 .